<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00124072</url>
  </required_header>
  <id_info>
    <org_study_id>CTSUSEARCH1</org_study_id>
    <nct_id>NCT00124072</nct_id>
  </id_info>
  <brief_title>Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine</brief_title>
  <acronym>SEARCH</acronym>
  <official_title>SEARCH: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SEARCH is a randomised, double-blind, multi-centre United Kingdom (UK) trial of 12,064
      patients with myocardial infarction (MI) prior to study entry which aims to demonstrate
      whether a more intensive cholesterol lowering regimen using 80 mg simvastatin daily produces
      a larger and worthwhile reduction in cardiovascular events compared with a standard 20 mg
      daily regimen and whether reducing blood homocysteine levels with a daily dose of folic acid
      2 mg + vitamin B12 1 mg compared with matching placebo produces a worthwhile reduction in
      vascular disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In observational studies, lower blood cholesterol concentrations are associated with lower
      coronary risk, without any clear threshold below which lower levels are not associated with
      lower risk. Cholesterol reduction with statins reduces such risk but there is uncertainty
      about whether greater reductions with more intensive statin therapy will produce greater
      benefits. Elevated blood homocysteine levels appear to be an independent marker of
      cardiovascular risk, but it is unknown whether taking vitamins to reduce homocysteine
      concentrations will translate into cardiovascular benefit.

      12,064 survivors of myocardial infarction have been randomised in a 2x2 factorial design to
      more intensive versus standard cholesterol-lowering treatment, using 80 mg or 20 mg daily
      simvastatin, and separately to homocysteine-lowering with folic acid plus vitamin B12 or
      matching placebo. Follow-up will continue until there are at least 2800 confirmed major
      vascular events (MVE), defined as non-fatal myocardial infarction, coronary death, stroke or
      arterial revascularisation. The primary outcome is the incidence of first MVE during the
      scheduled treatment period.

      SEARCH should provide reliable evidence of the effectiveness and safety of more intensive
      cholesterol-lowering for the reduction of major vascular events in a high-risk population,
      and of the effects of homocysteine-lowering with folic acid plus vitamin B12.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1998</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Vascular Events (MVE)</measure>
    <time_frame>6.7 years median follow-up</time_frame>
    <description>Major vascular events (MVE) defined as major coronary events (MCE [non-fatal MI, coronary death or coronary revascularisation]), non-fatal or fatal stroke, or peripheral revascularization (peripheral artery angioplasty or arterial surgery, including amputations), during the scheduled study treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MVEs Separately in Year 1 and in Later Years</measure>
    <time_frame>6.7 years median follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MVEs in Patients Subdivided Into 3 Groups by Baseline Low-density Lipoprotein (LDL)</measure>
    <time_frame>6.7 years median follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MVEs in Presence and Absence of the Other Factorial Treatment</measure>
    <time_frame>6.7 years median follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Coronary Events</measure>
    <time_frame>6.7 years median follow-up</time_frame>
    <description>Non-fatal MI, coronary death or coronary revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Strokes</measure>
    <time_frame>6.7 years median follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12064</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Simvastatin 20 mg + folic acid and B12</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 20 mg simvastatin once daily, and 2 mg folic acid with 1 mg vitamin B12 once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin 80 mg + folic acid and B12</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 80 mg simvastatin once daily, and 2 mg folic acid with 1 mg vitamin B12 once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin 20 mg + placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 20 mg simvastatin once daily, and placebo folic acid with placebo vitamin B12 once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin 80 mg + placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 80 mg simvastatin once daily, and placebo folic acid with placebo vitamin B12 once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin 20 mg daily</intervention_name>
    <description>Simvastatin 20 mg tablet once daily</description>
    <arm_group_label>Simvastatin 20 mg + folic acid and B12</arm_group_label>
    <arm_group_label>Simvastatin 20 mg + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Folic acid 2 mg + vitamin B12 1 mg daily</intervention_name>
    <description>Folic acid 2 mg + vitamin B12 1 mg tablet once daily</description>
    <arm_group_label>Simvastatin 20 mg + folic acid and B12</arm_group_label>
    <arm_group_label>Simvastatin 80 mg + folic acid and B12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin 80 mg daily</intervention_name>
    <description>Simvastatin 80 mg tablet once daily</description>
    <arm_group_label>Simvastatin 80 mg + folic acid and B12</arm_group_label>
    <arm_group_label>Simvastatin 80 mg + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo vitamin B12/folic acid tablet once daily</description>
    <arm_group_label>Simvastatin 20 mg + placebo</arm_group_label>
    <arm_group_label>Simvastatin 80 mg + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior myocardial infarction

          -  Statin therapy indicated

          -  No clear indication for folic acid

        Exclusion Criteria:

          -  No clear contraindication to study treatments

          -  Screening plasma total cholesterol &lt;3.5 mmol/l in patient already on statin therapy,
             or &lt;4.5 mmol/l in patient not on statin therapy

          -  Chronic liver disease

          -  Severe renal disease or evidence of renal impairment

          -  Inflammatory muscle disease

          -  Concurrent treatment with fibrates or high-dose niacin

          -  Concurrent treatment with cyclosporin (or condition likely to result in organ
             transplantation and the need for cyclosporin), nefazodone, methotrexate, systemic
             azole antifungal or systemic macrolide antibiotics

          -  Child bearing potential

          -  No other predominant medical problem (other than coronary heart disease [CHD]) which
             might limit compliance with 5 years of study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rory Collins, MB BS FRCP</last_name>
    <role>Study Director</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CTSU, Richard Doll Building, University of Oxford</name>
      <address>
        <city>Oxford</city>
        <state>Oxon</state>
        <zip>OX3 7LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2005</study_first_submitted>
  <study_first_submitted_qc>July 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2005</study_first_posted>
  <results_first_submitted>March 29, 2010</results_first_submitted>
  <results_first_submitted_qc>May 6, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 9, 2010</results_first_posted>
  <last_update_submitted>January 31, 2012</last_update_submitted>
  <last_update_submitted_qc>January 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2012</last_update_posted>
  <responsible_party>
    <name_title>Professor Rory Collins</name_title>
    <organization>University of Oxford</organization>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>Coronary heart disease</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Patient In: 28-SEP-1998, Last Patient Last Visit: 22-May-2008 Eighty-eight (88) sites in 3 countries: England 72, Scotland 12 and Wales 4.</recruitment_details>
      <pre_assignment_details>Patients entered a run-in period during which they received simvastatin 20 mg daily and placebo-vitamin tablets for 2 months. Eligible patients who completed run-in were then randomized in a 2x2 factorial blinded design between simvastatin 80 mg daily versus simvastatin 20 mg daily and folic acid 2 mg + vitamin B12 1 mg daily versus placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Simvastatin 20 mg + Folic Acid and B12</title>
          <description>Participants received 20 mg simvastatin once daily, and 2 mg folic acid with 1 mg vitamin B12 once daily</description>
        </group>
        <group group_id="P2">
          <title>Simvastatin 80 mg + Folic Acid and B12</title>
          <description>Participants received 80 mg simvastatin once daily, and 2 mg folic acid with 1 mg vitamin B12 once daily</description>
        </group>
        <group group_id="P3">
          <title>Simvastatin 20 mg + Placebo</title>
          <description>Participants received 20 mg simvastatin once daily, and placebo folic acid with placebo vitamin B12 once daily</description>
        </group>
        <group group_id="P4">
          <title>Simvastatin 80 mg + Placebo</title>
          <description>Participants received 80 mg simvastatin once daily, and placebo folic acid with placebo vitamin B12 once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3017"/>
                <participants group_id="P2" count="3016"/>
                <participants group_id="P3" count="3016"/>
                <participants group_id="P4" count="3015"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2503"/>
                <participants group_id="P2" count="2504"/>
                <participants group_id="P3" count="2524"/>
                <participants group_id="P4" count="2515"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="514"/>
                <participants group_id="P2" count="512"/>
                <participants group_id="P3" count="492"/>
                <participants group_id="P4" count="500"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up for Mortality</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up for Morbidity</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="499"/>
                <participants group_id="P2" count="484"/>
                <participants group_id="P3" count="471"/>
                <participants group_id="P4" count="480"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Simvastatin 20 mg + Folic Acid and B12</title>
          <description>Participants received 20 mg simvastatin once daily, and 2 mg folic acid with 1 mg vitamin B12 once daily</description>
        </group>
        <group group_id="B2">
          <title>Simvastatin 80 mg + Folic Acid and B12</title>
          <description>Participants received 80 mg simvastatin once daily, and 2 mg folic acid with 1 mg vitamin B12 once daily</description>
        </group>
        <group group_id="B3">
          <title>Simvastatin 20 mg + Placebo</title>
          <description>Participants received 20 mg simvastatin once daily, and placebo folic acid with placebo vitamin B12 once daily</description>
        </group>
        <group group_id="B4">
          <title>Simvastatin 80 mg + Placebo</title>
          <description>Participants received 80 mg simvastatin once daily, and placebo folic acid with placebo vitamin B12 once daily</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3017"/>
            <count group_id="B2" value="3016"/>
            <count group_id="B3" value="3016"/>
            <count group_id="B4" value="3015"/>
            <count group_id="B5" value="12064"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.2" spread="8.9"/>
                    <measurement group_id="B2" value="64.2" spread="8.9"/>
                    <measurement group_id="B3" value="64.2" spread="8.9"/>
                    <measurement group_id="B4" value="64.2" spread="8.9"/>
                    <measurement group_id="B5" value="64.2" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="513"/>
                    <measurement group_id="B2" value="514"/>
                    <measurement group_id="B3" value="513"/>
                    <measurement group_id="B4" value="512"/>
                    <measurement group_id="B5" value="2052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2504"/>
                    <measurement group_id="B2" value="2502"/>
                    <measurement group_id="B3" value="2503"/>
                    <measurement group_id="B4" value="2503"/>
                    <measurement group_id="B5" value="10012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3017"/>
                    <measurement group_id="B2" value="3016"/>
                    <measurement group_id="B3" value="3016"/>
                    <measurement group_id="B4" value="3015"/>
                    <measurement group_id="B5" value="12064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Major Vascular Events (MVE)</title>
        <description>Major vascular events (MVE) defined as major coronary events (MCE [non-fatal MI, coronary death or coronary revascularisation]), non-fatal or fatal stroke, or peripheral revascularization (peripheral artery angioplasty or arterial surgery, including amputations), during the scheduled study treatment period.</description>
        <time_frame>6.7 years median follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin 20 mg Daily</title>
            <description>Simvastatin 20 mg tablet once daily in the following arms: simvastatin 20 mg daily + folic acid 2 mg and vitamin B12 1 mg daily (active); simvastatin 20 mg daily + placebo vitamin B12/folic acid</description>
          </group>
          <group group_id="O2">
            <title>Simvastatin 80 mg Daily</title>
            <description>Simvastatin 80 mg tablet once daily in the following arms: simvastatin 80 mg daily + folic acid 2 mg and vitamin B12 1 mg daily (active); simvastatin 80 mg daily + placebo vitamin B12/folic acid</description>
          </group>
          <group group_id="O3">
            <title>Folic Acid 2 mg + Vitamin B12 1 mg Daily</title>
            <description>Folic acid 2 mg + vitamin B12 1 mg tablet once daily in the following arms: simvastatin 20 mg daily + folic acid 2 mg and vitamin B12 1 mg daily (active); simvastatin 80 mg daily + folic acid 2 mg and vitamin B12 1 mg daily (active)</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo vitamin B12/folic acid tablet once daily in the following arms: simvastatin 20 mg daily + placebo vitamin B12/folic acid; simvastatin 80 mg daily + placebo vitamin B12/folic acid</description>
          </group>
        </group_list>
        <measure>
          <title>Major Vascular Events (MVE)</title>
          <description>Major vascular events (MVE) defined as major coronary events (MCE [non-fatal MI, coronary death or coronary revascularisation]), non-fatal or fatal stroke, or peripheral revascularization (peripheral artery angioplasty or arterial surgery, including amputations), during the scheduled study treatment period.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6033"/>
                <count group_id="O2" value="6031"/>
                <count group_id="O3" value="6033"/>
                <count group_id="O4" value="6031"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1553"/>
                    <measurement group_id="O2" value="1477"/>
                    <measurement group_id="O3" value="1537"/>
                    <measurement group_id="O4" value="1493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MVEs Separately in Year 1 and in Later Years</title>
        <time_frame>6.7 years median follow-up</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MVEs in Patients Subdivided Into 3 Groups by Baseline Low-density Lipoprotein (LDL)</title>
        <time_frame>6.7 years median follow-up</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MVEs in Presence and Absence of the Other Factorial Treatment</title>
        <time_frame>6.7 years median follow-up</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Coronary Events</title>
        <description>Non-fatal MI, coronary death or coronary revascularisation</description>
        <time_frame>6.7 years median follow-up</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Strokes</title>
        <time_frame>6.7 years median follow-up</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6.7 years median follow-up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Simvastatin 20 mg Daily</title>
          <description>Simvastatin 20 mg tablet once daily in the following arms: simvastatin 20 mg daily + folic acid 2 mg and vitamin B12 1 mg daily (active); simvastatin 20 mg daily + placebo vitamin B12/folic acid</description>
        </group>
        <group group_id="E2">
          <title>Simvastatin 80 mg Daily</title>
          <description>Simvastatin 80 mg tablet once daily in the following arms: simvastatin 80 mg daily + folic acid 2 mg and vitamin B12 1 mg daily (active); simvastatin 80 mg daily + placebo vitamin B12/folic acid</description>
        </group>
        <group group_id="E3">
          <title>Folic Acid 2 mg + Vitamin B12 1 mg Daily</title>
          <description>Folic acid 2 mg + vitamin B12 1 mg tablet once daily in the following arms: simvastatin 20 mg daily + folic acid 2 mg and vitamin B12 1 mg daily (active); simvastatin 80 mg daily + folic acid 2 mg and vitamin B12 1 mg daily (active)</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo vitamin B12/folic acid tablet once daily in the following arms: simvastatin 20 mg daily + placebo vitamin B12/folic acid; simvastatin 80 mg daily + placebo vitamin B12/folic acid</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5037" subjects_at_risk="6033"/>
                <counts group_id="E2" subjects_affected="5024" subjects_at_risk="6031"/>
                <counts group_id="E3" subjects_affected="5068" subjects_at_risk="6033"/>
                <counts group_id="E4" subjects_affected="4993" subjects_at_risk="6031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="3484" subjects_at_risk="6033"/>
                <counts group_id="E2" subjects_affected="3547" subjects_at_risk="6031"/>
                <counts group_id="E3" subjects_affected="3531" subjects_at_risk="6033"/>
                <counts group_id="E4" subjects_affected="3500" subjects_at_risk="6031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>MVE</sub_title>
                <counts group_id="E1" subjects_affected="1553" subjects_at_risk="6033"/>
                <counts group_id="E2" subjects_affected="1477" subjects_at_risk="6031"/>
                <counts group_id="E3" subjects_affected="1537" subjects_at_risk="6033"/>
                <counts group_id="E4" subjects_affected="1493" subjects_at_risk="6031"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2.5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="479" subjects_at_risk="6033"/>
                <counts group_id="E2" subjects_affected="493" subjects_at_risk="6031"/>
                <counts group_id="E3" subjects_affected="480" subjects_at_risk="6033"/>
                <counts group_id="E4" subjects_affected="492" subjects_at_risk="6031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain or indigestion</sub_title>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="6033"/>
                <counts group_id="E2" subjects_affected="167" subjects_at_risk="6031"/>
                <counts group_id="E3" subjects_affected="156" subjects_at_risk="6033"/>
                <counts group_id="E4" subjects_affected="154" subjects_at_risk="6031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Tiredness or lethargy</sub_title>
                <counts group_id="E1" subjects_affected="165" subjects_at_risk="6033"/>
                <counts group_id="E2" subjects_affected="152" subjects_at_risk="6031"/>
                <counts group_id="E3" subjects_affected="162" subjects_at_risk="6033"/>
                <counts group_id="E4" subjects_affected="155" subjects_at_risk="6031"/>
              </event>
              <event>
                <sub_title>Other and unspecified symptom or problem</sub_title>
                <counts group_id="E1" subjects_affected="171" subjects_at_risk="6033"/>
                <counts group_id="E2" subjects_affected="174" subjects_at_risk="6031"/>
                <counts group_id="E3" subjects_affected="162" subjects_at_risk="6033"/>
                <counts group_id="E4" subjects_affected="183" subjects_at_risk="6031"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>CTSU Reception</name_or_title>
      <organization>CTSU, University of Oxford</organization>
      <phone>01865 743743</phone>
      <email>secretary@ctsu.ox.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

